Interim BNT162b2 LP.8.1-adapted COVID-19 Vaccine Effectiveness among Non-Immunocompromised Older Adults in California and Louisiana, August-December 2025

Related documents

• Detection and Genomic Characterization of Heartland and Bourbon Viruses in Amblyomma americanum ticks from Nebraska#660954
• Safety and immunogenicity of recombinant hepatitis E vaccine in healthy pregnant women between 14 and 34 weeks of gestation and non-pregnant women of reproductive age: Protocol for a Phase II, randomized, observer-blinded, placebo-controlled trial#660955
• Identifying Communities at Risk for Poor Health using Multidimensional vs. Unidimensional Neighborhood Disadvantage Indices#660956